This month, The Fass Lane discusses the results of a study assessing the difference between potassium-competitive acid blockers and proton pump inhibitors with respect to short-term adverse events.
The FDA has approved lirafugratinib (Lyrfigtu, Elevar) for the treatment of adults with previously treated unresectable, locally advanced, or metastatic cholangiocarcinoma harboring a fibroblast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results